MLN Matters Article (New) MM12631: April 2022 Update to the Fiscal Year (FY) 2022 Inpatient Prospective Payment System (IPPS)
This new Article comprises Subregulatory Guidance for coding needs for emergency use of Pfizer's PAXLOVID™ and Merck’s Molnupiravir and coding criteria for reprocessing inpatient claims involving PAXLOVID or Molnupiravir. MLN Matters (MM) Articles are based on information contained within Change Requests (CRs). In this case, this article is based on content within CR12631 that is posted on the CMS website at https://www.cms.gov/files/document/r11269CP.pdf.
Final
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: March 07, 2022
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.